The analysis of the expression levels of the BCL2 and c-MYC genes showed a decrease in the transcript level in patients with ovarian cancer compared to the control group (BCL2: 17.46% ± 3.26 vs. 100% ± 8.32; p < 0.05, c-MYC: 37.56% ± 8.16 vs. 100% ± 9.12; p < 0.05) (Figure 1). This evidence concerns the gene MYC and ovarian cancer.